Types of insulin drugs
Pro Research Analysisby 
Searched over 200M research papers
Types of Insulin Drugs: An Overview
Introduction to Insulin Therapy
Insulin therapy is a cornerstone in the management of diabetes, particularly for Type 1 Diabetes (T1D) and advanced Type 2 Diabetes (T2D). Since the discovery of insulin, various forms and delivery methods have been developed to improve glycemic control and patient compliance.
Types of Insulin
Rapid-Acting Insulin Analogs
Rapid-acting insulin analogs, such as insulin lispro, aspart, and glulisine, are designed to mimic the body's natural insulin response to meals. These insulins start working within 15 minutes of injection, peak in about 1 hour, and continue to work for 2 to 4 hours. They are often used in combination with long-acting insulins to provide better overall glucose control.
Short-Acting Insulin
Regular or short-acting insulin takes about 30 minutes to start working, peaks in 2 to 3 hours, and lasts for 3 to 6 hours. It is typically used before meals to control postprandial blood glucose levels.
Intermediate-Acting Insulin
Intermediate-acting insulin, such as NPH (Neutral Protamine Hagedorn), starts working in 2 to 4 hours, peaks in 4 to 12 hours, and lasts for 12 to 18 hours. It is often used in combination with rapid- or short-acting insulin.
Long-Acting Insulin Analogs
Long-acting insulin analogs, including insulin glargine, detemir, and degludec, provide a steady level of insulin for up to 24 hours or more. These insulins are typically used once daily to maintain basal insulin levels .
Ultra-Long-Acting Insulin
Ultra-long-acting insulins, such as insulin degludec, can last up to 42 hours, providing even more flexibility and reducing the risk of nocturnal hypoglycemia.
Innovative Insulin Delivery Methods
Inhaled Insulin
Inhaled insulin, such as Afrezza, offers a non-invasive alternative to injections. It is a rapid-acting insulin taken at the beginning of a meal. However, it is not suitable for everyone, particularly those with lung conditions.
Oral Insulin
Oral insulin formulations are being developed to improve patient compliance and reduce the discomfort associated with injections. Although promising, these formulations face challenges related to bioavailability and stability.
Adjunctive Therapies
Combination Therapies
Combining insulin with other glucose-lowering agents, such as GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors, can enhance glycemic control while minimizing insulin doses and associated side effects like weight gain and hypoglycemia .
Novel Insulin Sensitizers
Thiazolidinediones (TZDs) are insulin sensitizers that improve insulin action in peripheral tissues. Despite their efficacy, concerns over side effects have limited their use .
Conclusion
The landscape of insulin therapy continues to evolve with the development of new insulin analogs and innovative delivery methods. These advancements aim to improve glycemic control, reduce side effects, and enhance patient compliance. As research progresses, the future of insulin therapy looks promising, with the potential for more personalized and effective treatments for diabetes.
Sources and full results
Most relevant research papers on this topic